Amedeo Smart

Free Medical Literature Service

 

Amedeo

Autoimmune Disorders
  Free Subscription

Articles published in
Neurology
    May 2024
  1. SILBERMANN E, Spain RI
    Serum Neurofilament Light Chain for Multiple Sclerosis Relapses: Too Little Too Late?
    Neurology. 2024;102:e209456.
    >> Share

  2. FOX RJ, Cree BAC, de Seze J, Gold R, et al
    Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e209357.
    >> Share

  3. VALKO Y, Wirth MA, Fierz FC, Schesny MK, et al
    Accuracy of Repetitive Ocular Vestibular-Evoked Myogenic Potentials to Diagnose Myasthenia Gravis in Patients With Ptosis or Diplopia.
    Neurology. 2024;102:e209395.
    >> Share

  4. LIAO J, Lu Y, Lu Y, Huang Y, et al
    Cardiopulmonary Coupling Spectrogram as an Ambulatory Method for Assessing Sleep Disorders in Patients With Autoimmune Encephalitis.
    Neurology. 2024;102:e209302.
    >> Share

  5. MICHAELSON NM
    Right Brain: The Unraveling.
    Neurology. 2024;102:e209492.
    >> Share

  6. VYAS MV, Kapral MK, Alonzo R, Fang J, et al
    Proportion of Life Spent in Canada and the Incidence of Multiple Sclerosis in Permanent Immigrants.
    Neurology. 2024;102:e209350.
    >> Share

    April 2024
  7. ZOUVELOU V, Petrou EM, Strataki E, Vasileiou V, et al
    Pearls & Oy-sters: Thyroid-Associated Ophthalmopathy and Transient Neuromuscular Junction Disorder Due to Graves Disease.
    Neurology. 2024;102:e209282.
    >> Share

  8. DEMORTIERE S, Joubert B, Benaiteau M, Hilezian F, et al
    Anti-IgLON5 Disease With Inaugural Bilateral Neuropapillitis.
    Neurology. 2024;102:e209284.
    >> Share

  9. MOEHLMAN M, Kornbluh AB
    Teaching NeuroImage: Anti-NMDA Receptor Encephalitis Presenting With Cerebellitis in a Pediatric Patient.
    Neurology. 2024;102:e209259.
    >> Share


  10. Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria: A Longitudinal, Prospective, Multicenter Study.
    Neurology. 2024;102:e209214.
    >> Share

  11. OYAMA M, Holzer MT, Ohnuki Y, Saito Y, et al
    Pathologic Features of Anti-Ku Myositis.
    Neurology. 2024;102:e209268.
    >> Share

  12. OLIVE-CIRERA G, Bruijstens AL, Fonseca EG, Chen LW, et al
    MOG Antibodies Restricted to CSF in Children With Inflammatory CNS Disorders.
    Neurology. 2024;102:e209199.
    >> Share

  13. SPELMAN T, Simoneau G, Hyde R, Kuhelj R, et al
    Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study.
    Neurology. 2024;102:e208114.
    >> Share

  14. TOGNI CL, Frontzek K, Schubring-Giese M, Imbach LL, et al
    Posttransplant Anti-GABA(A) Receptor Antibody-Associated Autoimmune Encephalitis.
    Neurology. 2024;102:e209245.
    >> Share

  15. THAKOLWIBOON S, Dubey D
    Redefining Patient Evaluation in Anti-IgLON5 Disease: Anti-IgLON5 Disease Composite Score.
    Neurology. 2024;102:e209213.
    >> Share

  16. GAIG C, Gruter T, Heidbreder A, Sabater L, et al
    Development of a Composite Score for the Clinical Assessment of Anti-IgLON5 Disease.
    Neurology. 2024;102:e208101.
    >> Share

  17. KOTHAPALLI NP, Chompoopong P, McKeon A, Dubey D, et al
    Teaching Video NeuroImage: Adaptor-Related Protein-Complex-3 Subunit beta-2 Immunoglobulin-G-Associated Autoimmune Ataxia.
    Neurology. 2024;102:e209257.
    >> Share

  18. AGYEI P, Chen M, Guo Y, Perez CA, et al
    Pearls & Oy-sters: KLHL11 IgG Paraneoplastic-Associated Hearing Loss and Rhombencephalitis in a Woman With Metastatic Mullerian Tumor.
    Neurology. 2024;102:e209187.
    >> Share

    March 2024
  19. YOUNG A, Johnston JL
    Pearls & Oy-sters: Ocular Myasthenia Gravis: Central Ocular Motor Signs and Unilateral Visual Loss Caused by the Great Neuro-Ophthalmologic Impersonator.
    Neurology. 2024;102:e209260.
    >> Share

  20. AOTSUKA Y, Misawa S, Suichi T, Shibuya K, et al
    Prevalence, Clinical Profiles, and Prognosis of CIDP in Japanese Nationwide Survey: Analyses of 1,257 Diagnosis-Confirmed Patients.
    Neurology. 2024;102:e209130.
    >> Share

  21. MARRIE RA, Salter A
    Off-Road Testing: Outcome Reporting Bias in Multiple Sclerosis Trials.
    Neurology. 2024;102:e208099.
    >> Share

  22. LEMMENS CMC, van Amerongen S, Strijbis EM, Killestein J, et al
    Outcome Reporting Bias in Clinical Trials Researching Disease-Modifying Therapy in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e208032.
    >> Share

  23. BOURDETTE D, Wooliscroft L
    The Challenges of Treating Late-Onset Multiple Sclerosis.
    Neurology. 2024;102:e209146.
    >> Share

  24. MOURESAN EF, Mentesidou E, Berglund A, Mckay KA, et al
    Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
    Neurology. 2024;102:e208051.
    >> Share


  25. Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e209252.
    >> Share

  26. SALTER A, Lancia S, Kowalec K, Fitzgerald KC, et al
    Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;102:e209135.
    >> Share

  27. CHARD DT
    Chronically Active Lesions as a Trial Outcome in Multiple Sclerosis: A New Perspective on an Old Foe.
    Neurology. 2024;102:e209246.
    >> Share

  28. ARNOLD DL, Elliott C, Martin EC, Hyvert Y, et al
    Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.
    Neurology. 2024;102:e208058.
    >> Share

  29. PAPP V, Magyari M, Moller S, Sellebjerg F, et al
    Mortality of the Danish Nationwide AQP4 Antibody-Seropositive Neuromyelitis Optica Spectrum Disorder Patient Cohort.
    Neurology. 2024;102:e209147.
    >> Share

    February 2024
  30. MORGAN A, Li Y, Thompson NR, Milinovich A, et al
    Longitudinal Disability, Cognitive Impairment, and Mood Symptoms in Patients With Anti-NMDA Receptor Encephalitis.
    Neurology. 2024;102:e208019.
    >> Share

  31. RADZIK AM, Amezcua L, Anderson A, Gilmore S, et al
    Disparities by Race in Pregnancy Care and Clinical Outcomes in Women With Multiple Sclerosis: A Diverse Multicenter Cohort.
    Neurology. 2024;102:e208100.
    >> Share

  32. BRANCH A, Nuaaman MM, Appleton CT, Connaughton DM, et al
    Teaching NeuroImage: Extensive Brainstem and Striatal Involvement in Neuropsychiatric Systemic Lupus Erythematosus.
    Neurology. 2024;102:e209153.
    >> Share

  33. GALBUSERA R, Bahn E, Weigel M, Cagol A, et al
    Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e207966.
    >> Share

  34. WU J, Guo K, Liu J
    Partially Reversible FLAIR Hyperintensity Along the Brainstem Surface in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
    Neurology. 2024;102:e208064.
    >> Share

  35. NG HS, Zhu F, Zhao Y, Yao S, et al
    Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis.
    Neurology. 2024;102:e208006.
    >> Share

  36. BELLUCCI M, Castellano C, Marinelli L, Garbarino L, et al
    Patient With Rigidity and Fasciculations.
    Neurology. 2024;102:e208110.
    >> Share

  37. BRIDGE F, Brotherton J, Stankovich J, Sanfilippo PG, et al
    Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies.
    Neurology. 2024;102:e208059.
    >> Share

    January 2024
  38. GIBSON S, Mcgraw C
    Teaching NeuroImage: Cryptococcus in a Woman With Multiple Sclerosis on Fingolimod.
    Neurology. 2024;102:e208027.
    >> Share

  39. ANTOZZI C, Guptill J, Bril V, Gamez J, et al
    Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis.
    Neurology. 2024;102:e207937.
    >> Share

  40. MCGINLEY MP, Harvey T, Lopez R, Ontaneda D, et al
    Geographic Disparities in Access to Neurologists and Multiple Sclerosis Care in the United States.
    Neurology. 2024;102:e207916.
    >> Share

  41. HABIB AA, Sacks N, Cool C, Durgapal S, et al
    Hospitalizations and Mortality From Myasthenia Gravis.
    Neurology. 2024;102:e207863.
    >> Share

  42. LANGER-GOULD A, Sotirchos ES, Bourdette D
    Rituximab for Multiple Sclerosis.
    Neurology. 2024;102:e208063.
    >> Share

  43. GALETTA S, Brownlee W
    Assignment Completed.
    Neurology. 2024;102:e207913.
    >> Share

  44. TUR C, Rocca MA
    Progression Independent of Relapse Activity in Multiple Sclerosis.
    Neurology. 2024;102:e207936.
    >> Share

  45. VIDAL-JORDANA A, Rovira A, Calderon W, Arrambide G, et al
    Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria.
    Neurology. 2024;102:e200805.
    >> Share

  46. CAGOL A, Benkert P, Melie-Garcia L, Schaedelin SA, et al
    Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS.
    Neurology. 2024;102:e207768.
    >> Share

  47. VLAHOVIC L, McDonald J, Hinman J, Tomczak A, et al
    Prevalence, Demographic, and Clinical Factors Associated With Cognitive Dysfunction in Patients With Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2024;102:e207965.
    >> Share

  48. ALKABIE S, Gray MT, Lau JC, Barra L, et al
    Teaching NeuroImage: Unilateral Primary Angiitis of the CNS.
    Neurology. 2024;102:e208018.
    >> Share

    December 2023
  49. ROLLOT F, Uhry Z, Dantony E, Vukusic S, et al
    Comparison of 2 Methods for Estimating Multiple Sclerosis-Related Mortality.
    Neurology. 2023;101:e2483-e2496.
    >> Share

  50. SUNSHINE A, Mandle QJ, Cabal Herrera AM, Zapanta B, et al
    Pearls & Oy-sters: Leber Hereditary Optic Neuropathy-Plus Masquerading as Neuromyelitis Optica Spectrum Disorder in a 2-Year-Old Child.
    Neurology. 2023;101:e2585-e2588.
    >> Share

  51. GUINEBRETIERE O, Nedelec T, Gantzer L, Lekens BB, et al
    Association Between Diseases and Symptoms Diagnosed in Primary Care and the Subsequent Specific Risk of Multiple Sclerosis.
    Neurology. 2023 Dec 5:10.1212/WNL.0000000000207981.
    >> Share

    November 2023
  52. LI X, Stitt D, Lanzino G, Giannini C, et al
    Teaching NeuroImage: Pachymeningitis and Aortitis as the Initial Presentation of Granulomatosis With Polyangiitis.
    Neurology. 2023;101:979-980.
    >> Share

    October 2023
  53. SRIVASTAVA I, Van Haren K
    Immunotherapy in Autoimmune Encephalitis: So Many Options, So Few Guidelines.
    Neurology. 2023 Oct 25:10.1212/WNL.0000000000208026.
    >> Share

  54. BOURDETTE D, Silbermann E
    What Are the Risks of Guillain-Barre Syndrome Following SARS-CoV-2 Infection and COVID-19 Vaccination?
    Neurology. 2023 Oct 18:10.1212/WNL.0000000000207998.
    >> Share

  55. BISHARA H, Arbel A, Barnett-Griness O, Bloch S, et al
    Association Between Guillain-Barre Syndrome and COVID-19 Infection and Vaccination: A Population-Based Nested Case-Control Study.
    Neurology. 2023 Oct 18:10.1212/WNL.0000000000207900.
    >> Share

  56. YANG JH, Liu EN, Nguyen L, Dunn-Pirio A, et al
    Survival Analysis of Immunotherapy Effects on Relapse Rate in Pediatric and Adult Autoimmune Encephalitis.
    Neurology. 2023 Oct 12:10.1212/WNL.0000000000207746.
    >> Share

  57. GUASP M, Dalmau J
    Searching for Neuronal Antibodies in Psychiatric Diseases: Uncertain Findings and Implications.
    Neurology. 2023;101:656-660.
    >> Share

  58. SOTIRCHOS ES, Hu C, Smith MD, Lord HN, et al
    Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis.
    Neurology. 2023 Oct 10:10.1212/WNL.0000000000207957.
    >> Share

  59. LE VU S, Bertrand M, Botton J, Jabagi MJ, et al
    Risk of Guillain-Barre Syndrome Following COVID-19 Vaccines: A Nationwide Self-controlled Case Series Study.
    Neurology. 2023 Oct 3:10.1212/WNL.0000000000207847.
    >> Share

    September 2023
  60. COBO-CALVO A, Tur C, Otero-Romero S, Carbonell-Mirabent P, et al
    Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating Event.
    Neurology. 2023;101:e1280-e1292.
    >> Share

  61. PALLADINO R, Strijbis EM
    How Far Are We in Translating the Multiple Sclerosis Prodromes in Clinical Practice?
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207989.
    >> Share

  62. CHERTCOFF AS, Yusuf F, Zhu F, Evans C, et al
    Psychiatric Comorbidity During the Prodromal Period in Patients With Multiple Sclerosis.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207843.
    >> Share

  63. HUPPKE BM, Reinert M, Hummel-Abmeier H, Stark W, et al
    Pretreatment Neurofilament Light Chain Serum Levels, Early Disease Severity, and Treatment Response in Pediatric Multiple Sclerosis.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207791.
    >> Share

  64. ALMRAMHI MM, Finan C, Storm CS, Schmidt AF, et al
    Exploring the Role of Plasma Lipids and Statins Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study.
    Neurology. 2023 Sep 1:10.1212/WNL.0000000000207777.
    >> Share

  65. BUYUKKURT A, Harroud A
    The Potential to Inform Statin Use in Multiple Sclerosis Through Human Genetics [re: WNL-2023-000524].
    Neurology. 2023 Sep 1:10.1212/WNL.0000000000207773.
    >> Share

    August 2023
  66. JACOBS BC
    [Correction] CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barre Syndrome.
    Neurology. 2023 Aug 29:10.1212/WNL.0000000000207874.
    >> Share

  67. FANG CEH, Bokre D, Wong SH
    Clinical Characteristics Associated With Secondary Generalization in Ocular Myasthenia Gravis Patients: A Systematic Review and Meta-analysis.
    Neurology. 2023 Aug 29:10.1212/WNL.0000000000207642.
    >> Share

  68. BSTEH G, Hegen H, Altmann P, Auer M, et al
    Diagnostic Performance of Adding the Optic Nerve Region Assessed by Optical Coherence Tomography to the Diagnostic Criteria for Multiple Sclerosis.
    Neurology. 2023;101:e784-e793.
    >> Share

  69. GRAVES JS
    Cell Specific Aging in Multiple Sclerosis.
    Neurology. 2023 Aug 4:10.1212/WNL.0000000000207679.
    >> Share

  70. MALTBY V, Xavier A, Ewing E, Campagna MP, et al
    Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis.
    Neurology. 2023 Aug 4:10.1212/WNL.0000000000207489.
    >> Share

    July 2023
  71. BRAYO P, Serrano E, Thakkar RS, Osborne B, et al
    Pearls & Oy-sters: Syndrome of Inappropriate Antidiuretic Hormone Secretion Presenting as Neuromyelitis Optica Spectrum Disorder Flare.
    Neurology. 2023;101:e455-e458.
    >> Share

  72. HACOHEN Y, Tur C
    Treatment De-escalation in AQP4-Ab Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2023;101:153-154.
    >> Share

  73. DEMUTH S, Collongues N, Audoin B, Ayrignac X, et al
    Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2023;101:e438-e450.
    >> Share

  74. FADDA G, Cardenas de la Parra A, O'Mahony J, Waters P, et al
    Deviation From Normative Whole Brain and Deep Gray Matter Growth in Children With MOGAD, MS, and Monophasic Seronegative Demyelination.
    Neurology. 2023;101:e425-e437.
    >> Share

  75. QUINN C, Moulton K, Farwell M, Le W, et al
    Imaging With PET/CT of Diffuse CD8 T Cell Infiltration of Skeletal Muscle in Patients with Inclusion Body Myositis.
    Neurology. 2023 Jul 24:10.1212/WNL.0000000000207596.
    >> Share

  76. COUSTAL C, Goulabchand R, Labauge P, Guilpain P, et al
    Clinical, Radiologic, and Immunologic Features of Patients With CTLA4 Deficiency With Neurologic Involvement.
    Neurology. 2023 Jul 24:10.1212/WNL.0000000000207609.
    >> Share

  77. SCHWEITZER F, Laurent S, Cortese I, Fink GR, et al
    Progressive Multifocal Leukoencephalopathy: Pathogenesis, Diagnostic Tools, and Potential Biomarkers of Response to Therapy.
    Neurology. 2023 Jul 24:10.1212/WNL.0000000000207622.
    >> Share

  78. LONGBRAKE E, Kalincik T
    Early Treatment for Multiple Sclerosis: Time Is Brain.
    Neurology. 2023 Jul 19:10.1212/WNL.0000000000207754.
    >> Share

  79. EHRHARDT H, Lambe J, Moussa H, Vasileiou ES, et al
    Effects of Ibudilast on Retinal Atrophy in Progressive Multiple Sclerosis Subtypes: Post-Hoc Analyses of the SPRINT-MS Trial.
    Neurology. 2023 Jul 17:10.1212/WNL.0000000000207551.
    >> Share

  80. HOSHINA Y, Wright MA, Warner JE, Richards T, et al
    Pearls & Oy-sters: ATX-FGF14 Mimicking Autoimmune Pathology.
    Neurology. 2023 Jul 17:10.1212/WNL.0000000000207590.
    >> Share

  81. BENNETT JL
    Sprinting to the Finish: Optical Coherence Tomography, Retinal Atrophy, and Neurodegeneration in Progressive Multiple Sclerosis.
    Neurology. 2023 Jul 17:10.1212/WNL.0000000000207607.
    >> Share

  82. LEVIT E, Leon J, Lincoln MR
    Pearls & Oy-sters: Homozygous Complement Factor I Deficiency Presenting as Fulminant Relapsing Complement-Mediated CNS Vasculitis.
    Neurology. 2023;101:e220-e223.
    >> Share

  83. JAIN A, Arena VP, Steigerwald C, Borja MJ, et al
    Pearls and Oy-sters: CSF1R-Related Leukoencephalopathy With Spinal Cord Lesions Mimicking Multiple Sclerosis.
    Neurology. 2023 Jul 5:10.1212/WNL.0000000000207502.
    >> Share

  84. BAARS AE, Van Doorn PA, Jacobs BC, Kuitwaard K, et al
    Author Response: SARS-CoV-2 Vaccination Safety in Guillain-Barre Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy.
    Neurology. 2023;101:51.
    >> Share

  85. HARTH CE
    Reader Response: SARS-CoV-2 Vaccination Safety in Guillain-Barre Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy.
    Neurology. 2023;101:50-51.
    >> Share

  86. TOOSY AT, Vidal-Jordana A
    Is the Optic Nerve Overdue as a Criterion to Support the Diagnosis of Multiple Sclerosis?
    Neurology. 2023 Jul 3:10.1212/WNL.0000000000207625.
    >> Share

    June 2023
  87. KOCH-HENRIKSEN N
    Worldwide Disparity in the Effectiveness of the Diagnostic Process in Multiple Sclerosis.
    Neurology. 2023 Jun 30:10.1212/WNL.0000000000207530.
    >> Share

  88. SOLOMON AJ, Marrie RA, Viswanathan S, Correale J, et al
    Global Barriers to the Diagnosis of Multiple Sclerosis: Data From the Multiple Sclerosis International Federation Atlas of MS, Third Edition.
    Neurology. 2023 Jun 15:10.1212/WNL.0000000000207481.
    >> Share

  89. ROTSTEIN D, Schneider R
    A Birth Year Cohort and What It Can Reveal About Lipid Mediators as Putative Biomarkers of Progression in Multiple Sclerosis.
    Neurology. 2023 Jun 8:10.1212/WNL.0000000000207605.
    >> Share

  90. BROOS JY, Loonstra FC, de Ruiter LRJ, Gouda MMTEE, et al
    Association of Arachidonic Acid-Derived Lipid Mediators With Disease Severity in Patients With Relapsing and Progressive Multiple Sclerosis.
    Neurology. 2023 Jun 8:10.1212/WNL.0000000000207459.
    >> Share

  91. KOWALEC K, Fitzgerald KC, Salter A, Dolovich C, et al
    Polygenicity of Comorbid Depression in Multiple Sclerosis.
    Neurology. 2023 Jun 8:10.1212/WNL.0000000000207457.
    >> Share

    May 2023
  92. SUN H, Zhang S, Yu T, Zhou D, et al
    Teaching NeuroImage: Primary CNS Vasculitis Mimicking Intracranial Tumor.
    Neurology. 2023;100:1072-1073.
    >> Share

  93. BRENNER J, Mariotto S, Bastiaansen AEM, Paunovic M, et al
    Predictive Value of Serum Neurofilament Light Chain Levels in Anti-NMDA Receptor Encephalitis.
    Neurology. 2023;100:e2204-e2213.
    >> Share

  94. KUNCHOK A, Dalmau J
    Can Neurofilament Light Chain Be Utilized as a Biomarker of Disease Severity, Activity, and Outcomes in Anti-NMDA Receptor Encephalitis?
    Neurology. 2023;100:991-992.
    >> Share

  95. SCHEEL M, Pruss H, Finke C
    Reader Response: Teaching NeuroImage: Atypical Unilateral Cortical Ribboning in Anti-NMDA Receptor Encephalitis.
    Neurology. 2023;100:887.
    >> Share

  96. GANESH A, Galetta S
    Editors' Note: Teaching NeuroImage: Atypical Unilateral Cortical Ribboning in Anti-NMDA Receptor Encephalitis.
    Neurology. 2023;100:886.
    >> Share

  97. BUDHRAM A, Mirian A, Sharma M
    Reader Response: Teaching NeuroImage: Atypical Unilateral Cortical Ribboning in Anti-NMDA Receptor Encephalitis.
    Neurology. 2023;100:886-887.
    >> Share

    April 2023
  98. LUSK JB, Hoffman MN, Clark AG, Bae J, et al
    Association Between Neighborhood Socioeconomic Status and 30-Day Mortality and Readmission for Patients With Common Neurologic Conditions.
    Neurology. 2023;100:e1776-e1786.
    >> Share


  99. Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis.
    Neurology. 2023 Apr 25:10.1212/WNL.0000000000207433.
    >> Share

  100. AL-HAKEM H, Doets AY, Stino AM, Zivkovic SA, et al
    Cerebrospinal Fluid Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barre Syndrome.
    Neurology. 2023 Apr 19:10.1212/WNL.0000000000207282.
    >> Share

  101. SEJVAR J
    Cerebrospinal Fluid In Guillain-Barre Syndrome: It's a Matter of Timing.
    Neurology. 2023 Apr 19:10.1212/WNL.0000000000207203.
    >> Share

  102. GUPTILL JT, Benatar M, Granit V, Habib AA, et al
    Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials.
    Neurology. 2023 Apr 19:10.1212/WNL.0000000000207278.
    >> Share

  103. LEAVITT VM
    The Mismeasure of Change: Better Cognitive Measurement Instruments are Urgently Needed for Multiple Sclerosis Research.
    Neurology. 2023 Apr 18:10.1212/WNL.0000000000207431.
    >> Share

  104. CASTROGIOVANNI N, Mostert J, Repovic P, Bowen JD, et al
    Longitudinal Changes in Cognitive Test Scores in Patients With Relapsing Remitting Multiple Sclerosis: An Analysis of the DECIDE Dataset.
    Neurology. 2023 Apr 18:10.1212/WNL.0000000000207301.
    >> Share

    March 2023
  105. KIM HJ, Palace J
    Should We test for IgG Antibodies Against MOG in Both Serum and CSF in Patients With Suspected MOGAD?
    Neurology. 2023;100:497-498.
    >> Share

  106. CARTA S, Cobo Calvo A, Armangue T, Saiz A, et al
    Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study.
    Neurology. 2023;100:e1095-e1108.
    >> Share

    February 2023
  107. PIZZOLATO UMETON R, Waltz M, Aaen GS, Benson L, et al
    Therapeutic Response in Pediatric Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2023;100:e985-e994.
    >> Share

  108. LALLA R, Narasimhan R, Abdalkader M, Virmani D, et al
    Teaching NeuroImage: Imaging and Pathologic Findings in SARS-CoV-2-Related Acute Demyelinating Encephalomyelitis.
    Neurology. 2023 Feb 16:10.1212/WNL.0000000000207095.
    >> Share

  109. LEWIS A, Galetta S
    Editors' Note: Teaching Video NeuroImage: Bilateral Hemifacial Spasm in Giant Cell Arteritis.
    Neurology. 2023;100:310-311.
    >> Share

  110. LEWIS A, Galetta S
    Editors' Note: Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD.
    Neurology. 2023;100:309.
    >> Share

  111. CORNBLATH W, Eggenberger E
    Reader Response: Teaching Video NeuroImage: Bilateral Hemifacial Spasm in Giant Cell Arteritis.
    Neurology. 2023;100:311.
    >> Share

  112. SECHI E, Defazio G, Erre GL, Solla P, et al
    Author Response: Teaching Video NeuroImage: Bilateral Hemifacial Spasm in Giant Cell Arteritis.
    Neurology. 2023;100:311-312.
    >> Share

  113. CAO S, Zhu Y, Xue Q, Xia M, et al
    Reader Response: Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD.
    Neurology. 2023;100:309-310.
    >> Share

  114. CHEN J, Shah S
    Author Response: Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD.
    Neurology. 2023;100:310.
    >> Share

    January 2023
  115. LEONHARD SE, van der Eijk AA, Willison HJ, Jacobs BC, et al
    Author Response: An International Perspective on Preceding Infections in Guillain-Barre Syndrome: The IGOS-1000 Cohort.
    Neurology. 2023;100:264.
    >> Share

  116. DEBNATH M, Nagappa M
    Reader Response: An International Perspective on Preceding Infections in Guillain-Barre Syndrome: The IGOS-1000 Cohort.
    Neurology. 2023;100:263-264.
    >> Share

  117. GANESH A, Galetta S
    Editors' Note: An International Perspective on Preceding Infections in Guillain-Barre Syndrome: The IGOS-1000 Cohort.
    Neurology. 2023;100:263.
    >> Share

  118. PATIL SA, Grossman S, Kenney R, Balcer LJ, et al
    Where's the Vision? The Importance of Visual Outcomes in Neurologic Disorders: The 2021 H. Houston Merritt Lecture.
    Neurology. 2023;100:244-253.
    >> Share


  119. Pathologic Features of Anti-Mi-2 Dermatomyositis.
    Neurology. 2023 Jan 24:10.1212/WNL.0000000000201611.
    >> Share

  120. CACCIAGUERRA L, Morris P, Tobin WO, Chen JJ, et al
    Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2023 Jan 23:10.1212/WNL.0000000000206820.
    >> Share

  121. HORTON MK, Robinson SC, Shao X, Quach H, et al
    A Cross-Trait, Mendelian Randomization Study to Investigate Whether Migraine Is a Risk Factor for Multiple Sclerosis.
    Neurology. 2023 Jan 11:10.1212/WNL.0000000000206791.
    >> Share

    December 2022
  122. DONCEL-MORIANO CUBERO A, Espigol G, Renu A
    Teaching NeuroImage: Bilateral Internal Carotid Artery Stenosis Due to Aggressive Giant Cell Arteritis.
    Neurology. 2022 Dec 23:10.1212/WNL.0000000000206823.
    >> Share

  123. BORDEA E, Hunter RM
    Excess Treatment Costs of Multiple Sclerosis: What Can We Learn From Longitudinal Population-Based Data?
    Neurology. 2022 Dec 23:10.1212/WNL.0000000000206804.
    >> Share

  124. GAVOILLE A, Rollot F, Casey R, Debouverie M, et al
    Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference.
    Neurology. 2022 Dec 23:10.1212/WNL.0000000000206774.
    >> Share

  125. BERGSLAND N, Dwyer MG, Jakimovski D, Tavazzi E, et al
    Association of Choroid Plexus Inflammation on MRI With Clinical Disability Progression Over 5 Years in Patients With Multiple Sclerosis.
    Neurology. 2022 Dec 21:10.1212/WNL.0000000000201608.
    >> Share

  126. BOFFA G, Signori A, Massacesi L, Mariottini A, et al
    Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.
    Neurology. 2022 Dec 21:10.1212/WNL.0000000000206750.
    >> Share

  127. MULLER J, Noteboom S, Granziera C, Schoonheim MM, et al
    Understanding the Role of the Choroid Plexus in Multiple Sclerosis as an MRI Biomarker of Disease Activity.
    Neurology. 2022 Dec 21:10.1212/WNL.0000000000206806.
    >> Share

  128. MULLER-JENSEN L, Kriedemann H, Anvari K, Huehnchen P, et al
    Complicated Monkeypox Infection in a Patient With Multiple Sclerosis and Fingolimod Treatment.
    Neurology. 2022 Dec 20:10.1212/WNL.0000000000206743.
    >> Share

    November 2022
  129. KHAKBAN A, Llorian ER, Michaux KD, Patten SB, et al
    Direct Health Care Costs Associated With Multiple Sclerosis: A Population-Based Cohort Study From 2001 to 2020 in British Columbia, Canada.
    Neurology. 2022 Nov 30:10.1212/WNL.0000000000201645.
    >> Share

  130. BARRERAS P, Vasileiou ES, Filippatou AG, Fitzgerald KC, et al
    Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease.
    Neurology. 2022;99:e2504-e2516.
    >> Share

  131. ZIEMSSEN T
    Reader Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use.
    Neurology. 2022;99:868.
    >> Share

  132. PARNETTI L, Gaetani L
    Author Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use.
    Neurology. 2022;99:869.
    >> Share

  133. DEERHAKE ME, Giarraputo J, Gupta M, Eckstein C, et al
    Journal Club: Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis.
    Neurology. 2022;99:854-857.
    >> Share

  134. LEWIS A, Galetta S
    Editors' Note: The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
    Neurology. 2022;99:818.
    >> Share

  135. BEBO BF
    Author Response: The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
    Neurology. 2022;99:819.
    >> Share

  136. VARGAS WS
    Reader Response: The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
    Neurology. 2022;99:818-819.
    >> Share

    October 2022
  137. LI L, Avina-Zubieta JA, Bernstein CN, Kaplan GG, et al
    Risk of Multiple Sclerosis Among Users of Antitumor Necrosis Factor Alpha in Four Canadian Provinces: A Population-Based Study.
    Neurology. 2022 Oct 28. pii: WNL.0000000000201472.
    >> Share


  138. Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study.
    Neurology. 2022 Oct 28. pii: WNL.0000000000201391.
    >> Share

  139. STRIJBIS EMM, Koch MW
    TNF Alfa Blockers and the Risk of Multiple Sclerosis.
    Neurology. 2022 Oct 28. pii: WNL.0000000000201629.
    >> Share

  140. DOBSON R, Bove R
    In Vitro Fertilization and Multiple Sclerosis: Evolving Treatments and Reducing Relapse Risk.
    Neurology. 2022;99:737-738.
    >> Share

  141. BRIL V, Szczudlik A, Vaitkus A, Rozsa C, et al
    A Randomized, Double-Blind, Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis.
    Neurology. 2022 Oct 21. pii: WNL.0000000000201501.
    >> Share

  142. DUBESSY AL, Stankoff B, Arnulf I
    Author Response: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
    Neurology. 2022;99:727.
    >> Share

  143. SIEGLER JE, Galetta S
    Editors' Note: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
    Neurology. 2022;99:726.
    >> Share

  144. SPARASCI D, Zecca C, Gobbi C, Manconi M, et al
    Reader Response: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
    Neurology. 2022;99:726-727.
    >> Share

  145. SNETSELAAR L, Cheek JJ, Fox SS, Healy HS, et al
    Efficacy of Diet on Fatigue and Quality of Life in Multiple Sclerosis: A Systematic Review and Network Meta-analysis of Randomized Trials.
    Neurology. 2022 Oct 18. pii: WNL.0000000000201371.
    >> Share

  146. SPAIN R, Piccio L, Langer-Gould AM
    The Role of Diet in Multiple Sclerosis: Food for Thought.
    Neurology. 2022 Oct 18. pii: WNL.0000000000201565.
    >> Share

  147. MURPHY OC, Calabresi PA, Gold DR
    Teaching Video NeuroImage: Dramatic Response to Topiramate in Acquired Pendular Nystagmus From Multiple Sclerosis.
    Neurology. 2022 Oct 11. pii: WNL.0000000000201452.
    >> Share

  148. GANESH A, Galetta S
    Editors' Note: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Neurology. 2022;99:630.
    >> Share

  149. BARRO C
    Reader Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Neurology. 2022;99:630-631.
    >> Share

  150. LEPPERT D, Kropshofer H, Haring D, Dahlke F, et al
    Author Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Neurology. 2022;99:631.
    >> Share

  151. CORTESE R, Carrasco FP, Tur C, Bianchi A, et al
    Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging.
    Neurology. 2022 Oct 3. pii: WNL.0000000000201465.
    >> Share

    September 2022
  152. B SYC-MAZUREK S, Chen JJ, Morris P, Sechi E, et al
    Frequency of New or Enlarging Lesions on MRI Outside of Clinical Attacks in Patients With MOG-Antibody-Associated Disease.
    Neurology. 2022 Sep 29. pii: WNL.0000000000201263.
    >> Share

  153. BAARS AE, Kuitwaard K, de Koning LC, Luijten LWG, et al
    SARS-CoV-2 Vaccination Safety in Guillain-Barre Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropath.
    Neurology. 2022 Sep 20. pii: WNL.0000000000201376.
    >> Share

  154. ALLEN JA
    SARS-CoV-2 Vaccination and Autoimmune Neuropathies: Rebalancing the Risk.
    Neurology. 2022 Sep 20. pii: WNL.0000000000201366.
    >> Share

  155. COTE-OROZCO JE, Velez-Tirado N
    Teaching NeuroImage: Hypothalamic Involvement in Neuromyelitis Optica Spectrum Disorder in a Child.
    Neurology. 2022;99:535-536.
    >> Share

  156. GANESH A, Galetta S
    Editors' Note: Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis.
    Neurology. 2022;99:489.
    >> Share

  157. VALE S
    Reader Response: Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis.
    Neurology. 2022;99:491.
    >> Share

  158. GUASP M, Dalmau J
    Author Response: Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis.
    Neurology. 2022;99:490.
    >> Share

  159. JEANTIN L, Plu I, Amador MDM, Maillart E, et al
    Pearls & Oy-sters: Spinal Cord Candidiasis Linked to CARD9 Deficiency Masquerading as a Longitudinally Extensive Transverse Myelitis.
    Neurology. 2022;99:475-479.
    >> Share

  160. CAROTENUTO A, Valsasina P, Schoonheim MM, Geurts JJ, et al
    Investigating Functional Network Abnormalities and Associations With Disability in Multiple Sclerosis.
    Neurology. 2022 Sep 12. pii: WNL.0000000000201264.
    >> Share

    August 2022
  161. BASTERRA PP, Nombela F, Iriarte P, Del Rincon CR, et al
    Proprioceptive Stimuli as a New Type of Trigger for Epilepsy in Stiff Person Syndrome.
    Neurology. 2022 Aug 31. pii: WNL.0000000000201196.
    >> Share

  162. CORDANO C, Nourbakhsh B, Yiu HH, Papinutto N, et al
    Differences in Age-Related Retinal and Cortical Atrophy Rates in Multiple Sclerosis.
    Neurology. 2022 Aug 29. pii: WNL.0000000000200977.
    >> Share

  163. VILLOSLADA P, Llufriu S
    Preventing Neurodegeneration in Multiple Sclerosis Is Required From the Earliest Stages of the Disease.
    Neurology. 2022 Aug 29. pii: WNL.0000000000201223.
    >> Share

  164. HWANG S, Garcia-Dominguez MA, Fitzgerald KC, Saylor DR, et al
    Association of Multiple Sclerosis Prevalence With Sociodemographic, Health Systems, and Lifestyle Factors on a National and Regional Level.
    Neurology. 2022 Aug 24. pii: WNL.0000000000200962.
    >> Share

  165. LOPEZ-JIMENEZ A, Gutierrez-Gutierrez G, Guerra-Hiraldo JD, Kurtis MM, et al
    Teaching Video NeuroImage: Hung-Up Reflex in Stiff Limb Syndrome.
    Neurology. 2022;99:356.
    >> Share

  166. SHAH SS, Morris P, Buciuc M, Tajfirouz D, et al
    Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD.
    Neurology. 2022;99:e851-e857.
    >> Share

  167. BRENTON JN, Florenzo B, Koshiya H, Min S, et al
    Six-Minute Walk as a Measure of Walking Capacity and Endurance in Patients With Pediatric-Onset Multiple Sclerosis.
    Neurology. 2022 Aug 19. pii: WNL.0000000000201098.
    >> Share

  168. LEONHARD SE, van der Eijk AA, Andersen H, Antonini G, et al
    An International Perspective on Preceding Infections in Guillain-Barre Syndrome: The IGOS-1000 Cohort.
    Neurology. 2022 Aug 18. pii: WNL.0000000000200885.
    >> Share

  169. ROOS I, Malpas C, Leray E, Casey R, et al
    Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2022 Aug 17. pii: WNL.0000000000201029.
    >> Share

  170. MCLAREN JR, Mitchell MK, Al-Maadid FM, Staley KJ, et al
    Clinical Reasoning: An 8-Year-Old With Acute Onset Ataxia.
    Neurology. 2022;99:305-310.
    >> Share

  171. DOBSON R, Bove R
    IVF and Multiple Sclerosis: Evolving Treatments and Reducing Relapse Risk.
    Neurology. 2022 Aug 11. pii: WNL.0000000000201242.
    >> Share

  172. MAINGUY M, Tillaut H, Degremont A, Le Page E, et al
    Assessing the Risk of Relapse Requiring Corticosteroids After In Vitro Fertilization in Women With Multiple Sclerosis.
    Neurology. 2022 Aug 11. pii: WNL.0000000000201027.
    >> Share

  173. O'MAHONY J, Salter A, Ciftci B, Fox RJ, et al
    Physical and Mental Health-Related Quality of Life Trajectories Among People With Multiple Sclerosis.
    Neurology. 2022 Aug 10. pii: WNL.0000000000200931.
    >> Share

  174. SECHI E, Gallus E, Solla P, Puggioni D, et al
    Teaching Video NeuroImage: Bilateral Hemifacial Spasm in Giant Cell Arteritis.
    Neurology. 2022;99:256-257.
    >> Share

  175. PIAZZA F, Caminiti SP, Zedde M, Presotto L, et al
    Association of Microglial Activation With Spontaneous ARIA-E and Cerebrospinal Fluid Levels of Anti-A Autoantibodies.
    Neurology. 2022 Aug 8. pii: WNL.0000000000200892.
    >> Share

  176. BSTEH G, Krajnc N, Riedl K, Altmann P, et al
    Retinal Layer Thinning After Optic Neuritis is Associated With Future Relapse Remission in Relapsing Multiple Sclerosis.
    Neurology. 2022 Aug 2. pii: WNL.0000000000200970.
    >> Share

    July 2022
  177. KUANG SY, Li Y, Yang SL, Han X, et al
    Child Neurology: Aicardi-Goutieres Syndrome Presenting as Recurrent Ischemic Stroke.
    Neurology. 2022 Jul 8. pii: WNL.0000000000200952.
    >> Share

    June 2022
  178. KENNEY RC, Liu M, Hasanaj L, Joseph B, et al
    The Role of OCT Criteria and Machine Learning in Multiple Sclerosis and Optic Neuritis Diagnosis.
    Neurology. 2022 Jun 28. pii: WNL.0000000000200883.
    >> Share

  179. TOOSY AT, Eshaghi A
    Machine Learning Utility for Optical Coherence Tomography in Multiple Sclerosis: Is the Future Now?
    Neurology. 2022 Jun 28. pii: WNL.0000000000200862.
    >> Share

  180. FREEDMAN MS, Pozzilli C, Havrdova EK, Lemle A, et al
    Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results from Randomized Phase 2b Core and Extension Studies.
    Neurology. 2022 Jun 6. pii: WNL.0000000000200606.
    >> Share

    May 2022
  181. SOTIRCHOS ES, Vasileiou ES, Filippatou AG, Fitzgerald KC, et al
    Association of Serum Neurofilament Light Chain With Inner Retinal Layer Thinning in Multiple Sclerosis.
    Neurology. 2022 May 26. pii: WNL.0000000000200778.
    >> Share

  182. GRAVES J
    Identifying Multiple Sclerosis Activity: Do the Eyes Have It?
    Neurology. 2022 May 26. pii: WNL.0000000000200903.
    >> Share

  183. YANG JH, Graves JS
    Cancer Screening in Patients With Multiple Sclerosis: Are We Doing Enough?
    Neurology. 2022;98:737-738.
    >> Share

  184. LANGER-GOULD AM, Gonzales EG, Smith JB, Li BH, et al
    Racial and Ethnic Disparities in Multiple Sclerosis Prevalence.
    Neurology. 2022;98:e1818-e1827.
    >> Share

  185. GROOME PA, Webber C, Maxwell CJ, McClintock C, et al
    Multiple Sclerosis and the Cancer Diagnosis: Diagnostic Route, Cancer Stage, and the Diagnostic Interval in Breast and Colorectal Cancer.
    Neurology. 2022;98:e1798-e1809.
    >> Share

    April 2022
  186. WU Q, Zhao CW, Dai S
    Teaching Video NeuroImage: Generalized Reflex Myoclonus in Autoimmune Hepatitis-Primary Biliary Cholangitis Overlap Syndrome.
    Neurology. 2022 Apr 29. pii: WNL.0000000000200733.
    >> Share

  187. YANG JH, Graves JS
    Cancer Screening in Patients With Multiple Sclerosis: Are We Doing Enough?
    Neurology. 2022 Apr 28. pii: WNL.0000000000200366.
    >> Share

  188. HAMILTON R, Ciccarelli O
    Multiple Sclerosis Incidence in Black Patients: It's Time to Do Away With a Racial Medical Myth.
    Neurology. 2022 Apr 28. pii: WNL.0000000000200309.
    >> Share

  189. LANGER-GOULD AM, Gonzales EG, Smith JB, Li BH, et al
    Racial and Ethnic Disparities in Multiple Sclerosis Prevalence.
    Neurology. 2022 Apr 28. pii: WNL.0000000000200151.
    >> Share

  190. GROOME PA, Webber C, Maxwell CJ, McClintock C, et al
    Multiple Sclerosis and the Cancer Diagnosis: Diagnostic Route, Cancer Stage, and the Diagnostic Interval in Breast and Colorectal Cancer.
    Neurology. 2022 Apr 28. pii: WNL.0000000000200163.
    >> Share

  191. ROTSTEIN D, Solomon JM, Sormani MP, Montalban X, et al
    Association of No Evidence of Disease Activity With No Long-term Disability Progression in Multiple Sclerosis: A Systematic Review and Meta-analysis.
    Neurology. 2022 Apr 26. pii: WNL.0000000000200549.
    >> Share

  192. OKAI AF, Howard AM, Williams MJ, Brink JD, et al
    Advancing Care and Outcomes for African American Patients With Multiple Sclerosis.
    Neurology. 2022 Apr 25. pii: WNL.0000000000200791.
    >> Share

  193. PORTACCIO E, Bellinvia A, Razzolini L, Pasto L, et al
    Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset.
    Neurology. 2022;98:e1626-e1636.
    >> Share

  194. SWART G, Balgobind S, Chan C, Fulham M, et al
    Spinal Cord Presentation of Biopsy-Proven PET-Positive Giant Cell Arteritis.
    Neurology. 2022 Apr 15. pii: WNL.0000000000200749.
    >> Share

  195. BEBO B, Cintina I, LaRocca N, Ritter L, et al
    Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
    Neurology. 2022 Apr 13. pii: WNL.0000000000200150.
    >> Share

  196. OSTKAMP P, Schwab N
    Effects of Latitude and Sunlight on Multiple Sclerosis Severity: Two Peas in a Pod?
    Neurology. 2022 Apr 11. pii: WNL.0000000000200105.
    >> Share

  197. VITKOVA M, Diouf I, Malpas C, Horakova D, et al
    Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study.
    Neurology. 2022 Apr 11. pii: WNL.0000000000200545.
    >> Share

  198. GUASP M, Martin-Aguilar L, Sabater L, Bioque M, et al
    Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis.
    Neurology. 2022;98:e1489-e1498.
    >> Share

  199. LEPPERT D, Kropshofer H, Haring DAA, Dahlke F, et al
    Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Neurology. 2022 Apr 4. pii: WNL.0000000000200258.
    >> Share

    March 2022
  200. GALLAY L, Fermon C, Lessard L, Weiss-Gayet M, et al
    Involvement of Type-I Interferon Signaling in Muscle Stem Cell Proliferation During Dermatomyositis.
    Neurology. 2022 Mar 29. pii: WNL.0000000000200271.
    >> Share

  201. PINAL-FERNANDEZ I, Greenberg SA
    Type I Interferons in Dermatomyositis Myoblasts: Toxic Effect and a Potential Autocrine Loop.
    Neurology. 2022 Mar 29. pii: WNL.0000000000200679.
    >> Share

  202. BOURDETTE D, Sormani MP
    Thinking Anew: Accelerating Clinical Trials of New Therapies for Progressive Multiple Sclerosis.
    Neurology. 2022 Mar 23. pii: WNL.0000000000200597.
    >> Share

  203. LI V, Leurent B, Barkhof F, Braisher M, et al
    Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis.
    Neurology. 2022 Mar 23. pii: WNL.0000000000200604.
    >> Share

  204. MOLIMARD A, Gitiaux C, Barnerias C, Audic F, et al
    Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis: The French Experience.
    Neurology. 2022 Mar 21. pii: WNL.0000000000200288.
    >> Share

  205. BRIDEL C, Killestein J, Teunissen C
    Author Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2022;98:471.
    >> Share

  206. KROPSHOFER H, Haring DA, Kappos L, Leppert D, et al
    Reader Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2022;98:470-471.
    >> Share

  207. LEWIS A, Galetta S
    Editors' Note: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2022;98:470.
    >> Share

  208. HUMMERT MW, Schoppe LM, Bellmann-Strobl J, Siebert N, et al
    Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease: CHANCE(NMO) Study.
    Neurology. 2022;98:e1184-e1196.
    >> Share

  209. SIMMONS SB, Ontaneda D
    Slowly Expanding Lesions: A New Target for Progressive Multiple Sclerosis Trials?
    Neurology. 2022 Mar 11. pii: WNL.0000000000200230.
    >> Share

  210. AZZOLINI F, Farina A, Gastaldi M, Barilaro A, et al
    Leptomeningeal Gadolinium Enhancement in Autoimmune GFAP-Astrocytopathy.
    Neurology. 2022 Mar 11. pii: WNL.0000000000200291.
    >> Share

  211. CALVI A, Carrasco FP, Tur C, Chard DT, et al
    Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis.
    Neurology. 2022 Mar 11. pii: WNL.0000000000200144.
    >> Share

  212. ZENG YH, Zhao M, Guo XX, Wang N, et al
    Cutaneous Lesions as a Clue to the Etiology of Extensive Intracranial Calcifications: Aicardi-Goutieres Syndrome.
    Neurology. 2022;98:417-418.
    >> Share

  213. LEVISON LS, Thomsen RW, Sindrup SH, Andersen H, et al
    Association Between Incident Cancer and Guillain-Barre Syndrome Development: A Nationwide Case-Control Study.
    Neurology. 2022 Mar 2. pii: WNL.0000000000200015.
    >> Share

  214. HAMILTON RH, Ciccarelli O
    Non-White Participants Matter in White Matter Disease Studies: The Importance of Diversity in Multiple Sclerosis Clinical Trials.
    Neurology. 2022;98:345-346.
    >> Share

    February 2022
  215. MARZOUGHI S, Marulanda L, Ngo D, Chen T, et al
    Pearls & Oy-sters: Delayed Diagnosis of Acute Motor Axonal Neuropathy With Cardiac Arrest.
    Neurology. 2022;98:336-339.
    >> Share

  216. LIE IA, Weeda MM, Mattiesing RM, Mol MAE, et al
    Relationship Between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis: A Systematic Review.
    Neurology. 2022 Feb 16. pii: WNL.0000000000200006.
    >> Share

  217. MCELWEE DECKER B, Thibault D, Davis KA, Willis AW, et al
    Population-Based Study of Nonelective Postpartum Readmissions in Women With Stroke, Migraine, Multiple Sclerosis, and Myasthenia Gravis.
    Neurology. 2022 Feb 15. pii: WNL.0000000000200007.
    >> Share

  218. HACOHEN Y, Ciccarelli O
    New Evidence for EBV Infection as a Cause of Multiple Sclerosis.
    Neurology. 2022 Feb 10. pii: WNL.0000000000200243.
    >> Share

  219. MAMMEN AL
    Inclusion Body Myositis: An Autoimmune or Myodegenerative Disease?
    Neurology. 2022 Feb 7. pii: WNL.0000000000200188.
    >> Share

  220. TORTORELLA C, Aiello A, Gasperini C, Agrati C, et al
    Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.
    Neurology. 2022;98:e541-e554.
    >> Share

    January 2022
  221. ONUORAH HM, Charron O, Meltzer E, Montague A, et al
    Enrollment of Non-White Participants and Reporting of Race and Ethnicity in Phase III Trials of Multiple Sclerosis DMTs: A Systematic Review.
    Neurology. 2022 Jan 19. pii: WNL.0000000000013230.
    >> Share

  222. CUTTER GR, Koch MW
    Multiple Sclerosis Diagnostic Criteria: Moving Ahead or Walking in Place?
    Neurology. 2022;98:12-13.
    >> Share

  223. FILIPPI M, Preziosa P, Meani A, Dalla Costa G, et al
    Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome: A MAGNIMS Study.
    Neurology. 2022;98:e1-e14.
    >> Share

    December 2021
  224. DOETS AY, Lingsma HF, Walgaard C, Islam B, et al
    Predicting Outcome in Guillain-Barre Syndrome: International Validation of the Modified Erasmus GBS Outcome Score.
    Neurology. 2021 Dec 22. pii: WNL.0000000000013139.
    >> Share

  225. MIRZA AI, Zhu F, Knox N, Forbes JD, et al
    Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome.
    Neurology. 2021 Dec 22. pii: WNL.0000000000013245.
    >> Share

  226. COSTA AF, Rodriguez A, Martinez P, Blanco DCM, et al
    Teaching Video NeuroImage: Uncommon Neuro-ophthalmic Finding in a Patient With Miller Fisher Syndrome and Past SARS-CoV-2 Infection.
    Neurology. 2021;97:e2431-e2432.
    >> Share

  227. SHELLY S, Klein CJ, Dyck PJB, Paul P, et al
    Neurofascin-155 Immunoglobulin Subtypes: Clinicopathologic Associations and Neurologic Outcomes.
    Neurology. 2021;97:e2392-e2403.
    >> Share

  228. SEBASTIAN P, Cherbuin N, Barcellos LF, Roalstad S, et al
    Association Between Time Spent Outdoors and Risk of Multiple Sclerosis.
    Neurology. 2021 Dec 8. pii: WNL.0000000000013045.
    >> Share

  229. GRAVES JS, Killestein J
    Reading the "T" Leaves of COVID-19 Vaccine Responses in Multiple Sclerosis.
    Neurology. 2021 Dec 8. pii: WNL.0000000000013166.
    >> Share

  230. TANBOON J, Inoue M, Saito Y, Tachimori H, et al
    Dermatomyositis: Muscle Pathology According to Antibody Subtypes.
    Neurology. 2021 Dec 6. pii: WNL.0000000000013176.
    >> Share

  231. NOWAK RJ, Coffey CS, Goldstein JM, Dimachkie MM, et al
    Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study.
    Neurology. 2021 Dec 2. pii: WNL.0000000000013121.
    >> Share

    November 2021
  232. NEUPERT DG, Rathke KM, Mikati MA
    Teaching Video NeuroImage: Hereditary Hyperekplexia Mimicking Tonic Seizures in an Infant.
    Neurology. 2021;97:e2248-e2249.
    >> Share

  233. TENCER J, Yum SW
    Teaching NeuroImage: Basal Ganglia T1 Hyperintensity and SWI Signal Diabetic Striatopathy in an 18-Year-Old Man With Type 1 Diabetes Mellitus.
    Neurology. 2021;97:e2148-e2149.
    >> Share

  234. DUMONCEAU AG, Ameli R, Rogemond V, Ruiz A, et al
    Glial Fibrillary Acidic Protein Autoimmunity: A French Cohort Study.
    Neurology. 2021 Nov 19. pii: WNL.0000000000013087.
    >> Share

    October 2021

  235. Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort: Cross-sectional Analysis of the Swedish GEMG Study.
    Neurology. 2021 Oct 29. pii: WNL.0000000000013021.
    >> Share

  236. AMATO A
    Author Response: Guillain-Barre Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial.
    Neurology. 2021;97:841-842.
    >> Share

  237. WILLER J
    Reader Response: Guillain-Barre Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial.
    Neurology. 2021;97:841.
    >> Share

  238. TINTORE M, Cobo-Calvo A, Carbonell P, Arrambide G, et al
    Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome.
    Neurology. 2021;97:e1641-e1652.
    >> Share

  239. AA HOGLUND RA, Meyer HE, Stigum H, Torkildsen O, et al
    Association of Body Mass Index in Adolescence and Young Adulthood and Long-term Risk of Multiple Sclerosis: A Population-Based Study.
    Neurology. 2021 Oct 25. pii: WNL.0000000000012957.
    >> Share

  240. KALINCIK T, Tremlett H, Ascherio A
    High BMI In Youths as a Modifiable Risk Factor for Multiple Sclerosis: Weighing Up the Evidence.
    Neurology. 2021 Oct 25. pii: WNL.0000000000012966.
    >> Share

  241. AGHAJAN Y, Mitchell RN, Bhattacharyya S, Hsu TY, et al
    Teaching NeuroImage: Bilateral Middle Cerebellar Peduncle Stroke in Giant Cell Arteritis.
    Neurology. 2021 Oct 19. pii: WNL.0000000000012953.
    >> Share

  242. JANDRIC D, Lipp I, Paling D, Rog D, et al
    Mechanisms of Network Changes in Cognitive Impairment in Multiple Sclerosis.
    Neurology. 2021 Oct 14. pii: WNL.0000000000012834.
    >> Share

  243. SANCHEZ CV, Theel E, Binnicker M, Toledano M, et al
    Autoimmune Encephalitis Post-SARS-CoV-2 Infection: Case Frequency, Findings, and Outcomes.
    Neurology. 2021 Oct 11. pii: WNL.0000000000012931.
    >> Share

  244. SIMPSON-YAP S, De Brouwer E, Kalincik T, Rijke N, et al
    Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
    Neurology. 2021 Oct 5. pii: WNL.0000000000012753.
    >> Share

  245. KILLESTEIN J, Schoonheim MM, Voskuhl RR
    B-Cell Depletion and COVID-19 Severity in Multiple Sclerosis: Remaining Challenges.
    Neurology. 2021 Oct 5. pii: WNL.0000000000012754.
    >> Share

  246. BONACCHI R, Meani A, Pagani E, Marchesi O, et al
    Association of Age at Onset With Gray Matter Volume and White Matter Microstructural Abnormalities in People With Multiple Sclerosis.
    Neurology. 2021 Oct 4. pii: WNL.0000000000012869.
    >> Share

  247. HACOHEN Y, Eshaghi A
    Multiple Sclerosis in Children and Adults: Does Age Matter?
    Neurology. 2021 Oct 4. pii: WNL.0000000000012866.
    >> Share

  248. VRENKEN H, Jenkinson M, Pham D, Guttmann CRG, et al
    Opportunities for Understanding MS Mechanisms and Progression With MRI Using Large-Scale Data Sharing and Artificial Intelligence.
    Neurology. 2021 Oct 4. pii: WNL.0000000000012884.
    >> Share

    September 2021
  249. ZHAO-FLEMING HH, Valencia Sanchez C, Sechi E, Inbarasu J, et al
    CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies.
    Neurology. 2021;97:e1351-e1358.
    >> Share

  250. MERLO D, Stankovich J, Bai C, Kalincik T, et al
    Association Between Cognitive Trajectories and Disability Progression in Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2021 Sep 23. pii: WNL.0000000000012850.
    >> Share

  251. MARRIE RA, Maxwell C, Mahar A, Ekuma O, et al
    Colorectal Cancer Survival in Multiple Sclerosis: A Matched Cohort Study.
    Neurology. 2021 Sep 15. pii: WNL.0000000000012634.
    >> Share

  252. TOBIN O
    Early Diagnosis and Treatment is Associated With Improved Outcomes in Patients With Multiple Sclerosis.
    Neurology. 2021 Sep 14. pii: WNL.0000000000012738.
    >> Share

  253. CAMELO-FILHO AE, Estephan EP, Heise CO, Zanoteli E, et al
    Teaching Video NeuroImage: Reflex Facilitation in Lambert-Eaton Myasthenic Syndrome.
    Neurology. 2021;97:e1168-e1169.
    >> Share

  254. MILLER JW
    Inflammation As A Target For Epilepsy Therapy: The Case of Natalizumab.
    Neurology. 2021 Sep 14. pii: WNL.0000000000012768.
    >> Share

  255. GOLDSCHMIDT C, Fox RJ
    Relationship Between Serum Neurofilament Light and Multiple Sclerosis Disability Progression: Clear as Mud.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012755.
    >> Share

  256. TOBIN WO, Kalinowska-Lyszczarz A, Weigand SD, Guo Y, et al
    Clinical Correlation of Multiple Sclerosis Immunopathologic Subtypes.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012782.
    >> Share

  257. BRIDEL C, Leurs CE, van Lierop ZY, van Kempen ZL, et al
    Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012752.
    >> Share

  258. RADCLIFFE C, Potnis K, Peng TJ, DeCroce-Movson E, et al
    Teaching NeuroImage: Papilledema and Pachymeningitis: An Atypical Presentation of Granulomatosis With Polyangiitis.
    Neurology. 2021;97:e1060-e1061.
    >> Share

  259. YEH EA, Bourdette D, Wiendl H
    Longer-Term Safety of B-Cell Therapy With Ocrelizumab in Multiple Sclerosis.
    Neurology. 2021 Sep 2. pii: WNL.0000000000012716.
    >> Share

  260. HAUSER SL, Kappos L, Montalban X, Craveiro L, et al
    Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis.
    Neurology. 2021 Sep 2. pii: WNL.0000000000012700.
    >> Share

  261. PALLADINO R, Chataway J, Majeed A, Marrie RA, et al
    Interface of Multiple Sclerosis, Depression, Vascular Disease, and Mortality: A Population-Based Matched Cohort Study.
    Neurology. 2021 Sep 1. pii: WNL.0000000000012610.
    >> Share

  262. SALTER A
    Assessment of Biological Interactions Between MS Status and Depression for Mortality.
    Neurology. 2021 Sep 1. pii: WNL.0000000000012615.
    >> Share

    August 2021
  263. RICE J, Xiang XM
    Comparing the Effectiveness of Therapies in People With Secondary Progressive Multiple Sclerosis.
    Neurology. 2021;97:e972-e974.
    >> Share

  264. DOBSON R, Salter A
    Differing Impact of Disease-Modifying Therapy on Relapse and Progression: Time to Consider Inflammation and Neuroprotection Separately?
    Neurology. 2021;97:407-408.
    >> Share

  265. KOCH MW, Mostert JP, Wolinsky JS, Lublin FD, et al
    Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2021 Aug 25. pii: WNL.0000000000012690.
    >> Share

  266. PETERSSON M, Feresiadou A, Jons D, Ilinca A, et al
    Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort: Cross-sectional Analysis of the Swedish GEMG Study.
    Neurology. 2021 Aug 10. pii: WNL.0000000000012604.
    >> Share

  267. KOCH MW, Mostert J, Zhang Y, Wolinsky JS, et al
    Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum.
    Neurology. 2021 Aug 10. pii: WNL.0000000000012603.
    >> Share

  268. FREY J, Kramer J, Castellani R, Sriwastava S, et al
    Clinical Reasoning: A 47-Year-Old With Headache, Vertigo, and Double Vision.
    Neurology. 2021;97:e535-e539.
    >> Share

  269. STRUPP M, Frenzel C, Goldschagg N, Halmagyi GM, et al
    Teaching Video NeuroImage: One Bedside Test, 2 Clinical Signs: One Vestibular, the Other Ocular Motor.
    Neurology. 2021;97:e541-e542.
    >> Share

    July 2021
  270. KARCESKI S
    Myasthenia Gravis: Which Type of Surgery Is Best?
    Neurology. 2021;97:e433-e435.
    >> Share

  271. CHEN T
    Clinical Reasoning: A 68-Year-Old Man With Proximal Weakness and Seizures.
    Neurology. 2021;97:e423-e428.
    >> Share

  272. SECHI E, Krecke KN, Messina SA, Buciuc M, et al
    Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders.
    Neurology. 2021 Jul 14. pii: WNL.0000000000012467.
    >> Share

  273. RASMINSKY M
    GCA Squared.
    Neurology. 2021;97:90-91.
    >> Share

  274. NICHOLAS RS, Rhone EE, Mariottini A, Silber E, et al
    Autologous Haematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: a Real-world Case Series.
    Neurology. 2021 Jul 12. pii: WNL.0000000000012449.
    >> Share

  275. LISAK RP
    [Editorial] At the Junction Where It Happens: Antibodies to LRP4 and Agrin Are Pathogenic in Myasthenia Gravis [re: M/S #2020/169756].
    Neurology. 2021 Jul 7. pii: WNL.0000000000012471.
    >> Share

  276. YU Z, Zhang M, Jing H, Chen P, et al
    Characterization of LRP4/Agrin Antibodies From a Patient with Myasthenia Gravis.
    Neurology. 2021 Jul 7. pii: WNL.0000000000012463.
    >> Share

  277. HACOHEN Y, Kerr W, Waters P
    Intrathecal Production of MOG-IgG: Highlighting the Need for CSF Testing in Clinical Practice.
    Neurology. 2021;97:12-13.
    >> Share

  278. AKAISHI T, Takahashi T, Misu T, Kaneko K, et al
    Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2021;97:e1-e12.
    >> Share

  279. GUASP M, Gine-Serven E, Maudes E, Rosa-Justicia M, et al
    Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis.
    Neurology. 2021;97:e61-e75.
    >> Share

    June 2021
  280. GRAY-RONCAL K, Fitzgerald K, Ryerson LZ, Charvet L, et al
    Association of Disease Severity and Socioeconomic Status in Black and White Americans With Multiple Sclerosis.
    Neurology. 2021 Jun 30. pii: WNL.0000000000012362.
    >> Share

  281. ROOS I, Leray E, Casey R, Horakova D, et al
    Effects of High and Low Efficacy Therapy in Secondary Progressive Multiple Sclerosis.
    Neurology. 2021 Jun 30. pii: WNL.0000000000012354.
    >> Share

  282. MYERS KA
    Author Response: Teaching Video NeuroImages: Pathologic Yawning: A Sign of Brainstem Involvement in Acute Disseminated Encephalomyelitis?
    Neurology. 2021;96:1105.
    >> Share

  283. FUJIMORI J, Nakashima I
    Reader Response: Teaching Video NeuroImages: Pathologic Yawning: A Sign of Brainstem Involvement in Acute Disseminated Encephalomyelitis?
    Neurology. 2021;96:1104-1105.
    >> Share

  284. VILLACIEROS-ALVAREZ J, Ordas CM, Torres-Gaona G, Diez-Barrio A, et al
    Teaching Video NeuroImages: Anti-IgLON5 Disease: A Long-Course Presentation With a Response to Immunotherapy.
    Neurology. 2021;96:e2901-e2902.
    >> Share

  285. HUISKAMP M, Eijlers AJC, Broeders TAA, Pasteuning J, et al
    Longitudinal Network Changes and Conversion to Cognitive Impairment in Multiple Sclerosis.
    Neurology. 2021 Jun 7. pii: WNL.0000000000012341.
    >> Share

  286. PREZIOSA P, Schoonheim MM
    Ongoing Axonal Injury in Chronic Active Lesions in Multiple Sclerosis: In-Vivo Quantification Using Serum Neurofilament.
    Neurology. 2021 Jun 4. pii: WNL.0000000000012331.
    >> Share

  287. CAMPBELL CREE BA, Arnold DL, Chataway J, Chitnis T, et al
    Secondary Progressive Multiple Sclerosis: New Insights.
    Neurology. 2021 Jun 4. pii: WNL.0000000000012323.
    >> Share

  288. MAGGI P, Kuhle J, Schadelin S, van der Meer F, et al
    Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis.
    Neurology. 2021 Jun 4. pii: WNL.0000000000012326.
    >> Share

    May 2021
  289. SAN MARTIN AH, Cuadrado CA, Arbizu MG, Rabano-Suarez P, et al
    Autoimmune Septin-5 Disease Presenting as Spinocerebellar Ataxia and Nystagmus.
    Neurology. 2021 May 24. pii: WNL.0000000000012240.
    >> Share

  290. ROLLOT F, Fauvernier M, Uhry Z, Vukusic S, et al
    Effects of Age and Disease Duration on Excess Mortality in Patients With Multiple Sclerosis From a French Nationwide Cohort.
    Neurology. 2021 May 19. pii: WNL.0000000000012224.
    >> Share

  291. MARRIE RA, Maxwell C, Mahar A, Ekuma O, et al
    Breast Cancer Survival in Multiple Sclerosis: A Matched Cohort Study.
    Neurology. 2021 May 19. pii: WNL.0000000000012127.
    >> Share

  292. JOLLIFFE EA, Guo Y, Hardy TA, Morris PP, et al
    Clinical and Radiologic Features, Pathology, and Treatment of Balo Concentric Sclerosis.
    Neurology. 2021 May 19. pii: WNL.0000000000012230.
    >> Share

  293. TOOSY AT, Kapur K, Nair KV
    Is OCT a Viable Tool to Monitor Disease-Modifying Treatments in RRMS Yet?
    Neurology. 2021;96:927-928.
    >> Share

  294. DAY GS, Yarbrough MY, Kortvelyessy P, Pruss H, et al
    Prospective Quantification of CSF Biomarkers in Antibody-Mediated Encephalitis.
    Neurology. 2021;96:e2546-e2557.
    >> Share

  295. TITULAER MJ, Day GS
    Autoimmune Encephalitis in First Episode Psychoses: All Smoke and No Fire?
    Neurology. 2021 May 12. pii: WNL.0000000000012195.
    >> Share

  296. GIANNOCCARO MP, Liguori R
    Author Response: Comparison of Ice Pack Test and Single-Fiber EMG Diagnostic Accuracy in Patients Referred for Myasthenic Ptosis.
    Neurology. 2021;96:918-919.
    >> Share

  297. SILVESTRI N
    Reader Response: Comparison of Ice Pack Test and Single-Fiber EMG Diagnostic Accuracy in Patients Referred for Myasthenic Ptosis.
    Neurology. 2021;96:918.
    >> Share

  298. NERSESJAN V, McWilliam O, Krarup LH, Kondziella D, et al
    Autoimmune Encephalitis Related to Cancer Treatment With Immune Checkpoint Inhibitors: Systematic Review.
    Neurology. 2021 May 5. pii: WNL.0000000000012122.
    >> Share


  299. Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.
    Neurology. 2021 May 4. pii: WNL.0000000000011825.
    >> Share

  300. SOLIS-PAZMINO P, Baiu I, Lincango-Naranjo E, Trope W, et al
    Impact of the Surgical Approach to Thymectomy Upon Complete Stable Remission Rates in Myasthenia Gravis: A Meta-analysis.
    Neurology. 2021 May 4. pii: WNL.0000000000012153.
    >> Share

  301. FOX RJ, Kryscio RJ
    A New Way to Identify Promising Therapies for Progressive Multiple Sclerosis.
    Neurology. 2021;96:833-834.
    >> Share

  302. KOCH MW, Sage K, Kaur S, Kim J, et al
    Repurposing Domperidone in Secondary Progressive Multiple Sclerosis: A Simon 2-Stage Phase 2 Futility Trial.
    Neurology. 2021;96:e2313-e2322.
    >> Share

  303. BAR-OR A, Herman A, Stokmaier D
    Author Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Neurology. 2021;96:870.
    >> Share

  304. HAHN N
    Reader Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Neurology. 2021;96:870.
    >> Share

  305. SIEGLER JE, Galetta S
    Editors' Note: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Neurology. 2021;96:869.
    >> Share

    April 2021
  306. DUBESSY AL, Tezenas du Montcel S, Viala F, Assouad R, et al
    Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
    Neurology. 2021 Apr 30. pii: WNL.0000000000012120.
    >> Share

  307. ZOUVELOU V, Daponte A
    Teaching Video NeuroImages: Resolution of Ptosis After Forceful Eye Closure: Bedside Diagnosis of Myasthenia Gravis.
    Neurology. 2021 Apr 30. pii: WNL.0000000000012100.
    >> Share

  308. LEAVITT VM, Dobson R, Svennigsson A
    Perinatal Depression and Anxiety in Multiple Sclerosis: Treatable Distress.
    Neurology. 2021 Apr 28. pii: WNL.0000000000012101.
    >> Share

  309. SHELLY S, Mills JR, Dubey D, McKeon A, et al
    Clinical Utility of Striational Antibodies in Paraneoplastic and Myasthenia Gravis Paraneoplastic Panels.
    Neurology. 2021 Apr 26. pii: WNL.0000000000012050.
    >> Share

  310. SALAVISA M, Serrazina F, Pires P, Correia AS, et al
    Teaching Video NeuroImages: Infratentorial Multiple Sclerosis Relapse Presenting as Continuous Hemifacial Myokymia.
    Neurology. 2021 Apr 26. pii: WNL.0000000000012052.
    >> Share

  311. GASPERI C, Hapfelmeier A, Daltrozzo T, Schneider A, et al
    Systematic Assessment of Medical Diagnoses Preceding the First Diagnosis of Multiple Sclerosis.
    Neurology. 2021 Apr 26. pii: WNL.0000000000012074.
    >> Share

  312. SOLOMON AJ, Ascherio A
    Early Diagnosis of Multiple Sclerosis: Further Evidence for Missed Opportunity.
    Neurology. 2021 Apr 26. pii: WNL.0000000000012087.
    >> Share


  313. Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis.
    Neurology. 2021 Apr 23. pii: WNL.0000000000012021.
    >> Share

  314. EID K, Torkildsen OF, Aarseth J, Flemmen HO, et al
    Perinatal Depression and Anxiety in Women with Multiple Sclerosis: A Population-Based Cohort Study.
    Neurology. 2021 Apr 21. pii: WNL.0000000000012062.
    >> Share

  315. YEH WZ, Widyastuti PA, Van der Walt A, Stankovich J, et al
    Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.
    Neurology. 2021 Apr 20. pii: WNL.0000000000012084.
    >> Share

  316. SHELLY S, Shouman K, Paul P, Engelstad J, et al
    Expanding the Spectrum of Chronic Immune Sensory Polyradiculopathy: CISP-Plus.
    Neurology. 2021;96:e2078-e2089.
    >> Share

  317. NISHIDA H, Kohyama K, Kumada S, Takanashi JI, et al
    Evaluation of the Diagnostic Criteria for Anti-NMDA Receptor Encephalitis in Japanese Children.
    Neurology. 2021;96:e2070-e2077.
    >> Share

  318. COLLONGUES N, Alves Do Rego C, Bourre B, Biotti D, et al
    Pregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder.
    Neurology. 2021;96:e2006-e2015.
    >> Share

  319. LAMBE J, Risher H, Filippatou AG, Murphy OC, et al
    Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis.
    Neurology. 2021 Apr 7. pii: WNL.0000000000011933.
    >> Share

  320. BOURDETTE D, Killestein J
    Quelling Public Fears about Guillain-Barre Syndrome and COVID-19 Vaccination.
    Neurology. 2021 Apr 6. pii: WNL.0000000000011882.
    >> Share

  321. MARQUEZ LOZA AM, Holroyd KB, Johnson SA, Pilgrim DM, et al
    Guillain- Barre Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial: Temporal Associations Do Not Imply Causality.
    Neurology. 2021 Apr 6. pii: WNL.0000000000011881.
    >> Share

  322. ALLEN JA, Pasnoor M, Dimachkie MM, Ajroud-Driss S, et al
    Quantifying Treatment-Related Fluctuations in CIDP: Results of the GRIPPER Study.
    Neurology. 2021;96:e1876-e1886.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016